Systematic Review of Vancomycin Population Pharmacokinetic Models in Critically Ill Patients: A Focus on Model
Tianyu Xu1,2, Hao Sun1, Yujia Zhang1
1Department of Pharmacy, Shengjing Hospital of China Medical University, Shenyang 110004, China.
Abstract:
Objective: Several population pharmacokinetic (PopPK) studies of vancomycin in intensive care unit (ICU) patients have been reported. However, substantial heterogeneity exists across these studies, and their predictive performance remains uncertain owing to a lack of external validation. This study systematically reviews published PopPK models of vancomycin in critically ill patients and externally validated selected models using real-world data, with the aim of clarifying factors contributing to variability in vancomycin pharmacokinetic parameters and identifying knowledge gaps that require further investigation. Methods: Databases such as PubMed, EMBASE, and the Cochrane Library were searched for studies on vancomycin PopPK models in critically ill patients constructed using nonlinear mixed-effects methods. External validation of selected models was performed using the NONMEM software with external datasets. Results: A total of 16 PopPK studies of vancomycin in ICU patients were included. Factors such as renal function indicators, concomitant renal replacement therapy (RRT), and demographic characteristics significantly influenced vancomycin PopPK parameters in ICU patients. Serum creatinine levels and concomitant RRT significantly affected vancomycin clearance, with clearance increasing with higher creatinine clearance or the presence of RRT, whereas body weight significantly influenced the apparent volume of distribution, which increased with increasing body weight. External validation was performed for three of these models, but all models showed unsatisfactory external validation results, with poor predictive capability for the external validation datasets. Conclusions: The reported studies show variations in vancomycin PopPK parameters among ICU patients, with significant inter-individual variability. Clinical dosing should be adjusted based on patients' concomitant therapies, renal function, and body weight. Existing published models lack external validation, and the results of external validation have not been satisfactory. It is recommended that PopPK models undergo external validation to assess their predictive performance before application. Additionally, future research should place greater emphasis on external validation to thoroughly evaluate model performance.
Related Concept Videos
Pharmacokinetic Models: Overview
There are three primary types of models: empirical, compartment, and physiological. Empirical models, with minimal assumptions,...
Pharmacokinetic Models: Comparison and Selection Criterion
Physiological models take a detailed approach by considering specific molecular processes. They can predict drug distribution, metabolism, and elimination changes, providing a comprehensive understanding of how drugs interact with the body.
Analysis of Population Pharmacokinetic Data
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
Clearance Models: Compartment Models
Analysis Methods of Pharmacokinetic Data: Model and Model-Independent Approaches
The model approach uses mathematical models to describe changes in drug concentration over time. Pharmacokinetic models help characterize drug behavior in patients, predict drug concentration in the body fluids, calculate optimum dosage regimens, and evaluate the risk of toxicity. However, ensuring that the model fits the experimental data accurately...
